Skip to content
Wide Range of Medications Help 24/7: support@mexicanpharmacyking.com
Our Products

Myrbetriq (Mirabegron)

Active ingredient: Mirabegron
Indications:

Overactive bladder with urgency, frequency and urge incontinence

Manufacturer
Market supply varies
Airmail Shipping
No Tracking8–20 days$14.95
Express Shipping
Tracking3–10 days$30.00
Available Options
$2,169.42 MXN$119.99 USD
Ordering process

How It Works

  1. 1Step 01
    Choose a product in the catalog or find it with search.
  2. 2Step 02
    Select the option you need on the product page.
  3. 3Step 03
    Go to Cart and enter your contact and order details.
  4. 4Step 04
    Complete payment using the available payment method.
  5. 5Step 05
    Send a prescription to email after placing the order for medications that require a prescription.

Myrbetriq (mirabegron) is a beta-3 adrenergic agonist prescribed for selected overactive bladder symptoms, including urinary urgency and frequency, with treatment requiring review of blood pressure, bladder-emptying problems, other medicines and the extended-release tablet formulation.

Key Takeaways

  • Myrbetriq uses mirabegron, a beta-3 adrenergic agonist.
  • There are 4 50 mg quantity options, priced $119.99–$421.99 USD in total.
  • Extended-release tablets are not ordinary divisible immediate-release tablets.
  • Blood pressure and urinary retention are important monitoring issues.
  • Urinary urgency is a symptom, not a diagnosis by itself.

General Information

People with overactive bladder often describe planning journeys around bathrooms, waking repeatedly at night or worrying about sudden urgency when leaving home. Mirabegron is not a general cure for all urinary symptoms. Burning, blood in urine, fever, retention and other warning signs should prompt evaluation for infection, obstruction or a different urologic condition. When overactive bladder has been diagnosed, treatment may involve behavioral changes and medication together rather than relying on a tablet alone.

Overactive Bladder Symptoms

Myrbetriq contains mirabegron, a medicine used for symptoms of overactive bladder including urinary urgency, increased frequency and episodes of urge incontinence. These symptoms can interrupt work, sleep, travel and social activities, yet they do not identify one single disease. Urinary infection, poorly controlled diabetes, certain medicines, bladder obstruction and neurologic disorders can all influence bladder behavior. The prescribing clinician should examine the symptom pattern and investigate concerning findings before choosing treatment.

Mirabegron acts as a beta-3 adrenergic receptor agonist, relaxing the bladder’s detrusor muscle during the storage phase. This can improve the bladder’s capacity to hold urine and reduce sudden urgency. It does not eliminate the need for a pelvic or urinary evaluation when blood in urine, painful urination or significant difficulty emptying is present. A medicine designed to manage storage symptoms may not solve a problem arising from impaired bladder emptying.

Different From Antimuscarinics

Mirabegron belongs to a different pharmacologic group from antimuscarinic bladder medicines. This may be relevant to someone troubled by dry mouth or constipation on another drug, but side-effect profiles are not identical and the best alternative depends on the whole clinical picture.

Mirabegron can raise blood pressure and may worsen urinary retention in susceptible patients. Interactions with medicines metabolized by CYP2D6 are another reason to review the entire medication list before starting or changing therapy.

Older medicines for overactive bladder often act through muscarinic receptors and can cause dry mouth, constipation and other anticholinergic effects. Mirabegron uses a different receptor pathway and may be considered when antimuscarinic adverse effects are troublesome or when another treatment strategy is appropriate. The choice is not decided by which medicine is newer, however, because blood pressure, cardiovascular history, other drugs and urinary retention risk all need to be considered.

Behavioral measures remain important. A bladder diary can show fluid intake, urgency episodes, nighttime waking and the situations in which leakage occurs.

Pelvic-floor training, management of constipation, review of diuretic timing and appropriate fluid habits may improve symptoms alongside or before medication. The benefit of mirabegron is often easier to evaluate when the patient has recorded a baseline instead of relying on a general impression that bathroom trips are becoming more frequent.

Blood Pressure and Emptying

Mirabegron can increase blood pressure and is not appropriate for some patients with severely uncontrolled hypertension. A prescriber should know the patient’s current readings and cardiovascular history before beginning therapy and may arrange monitoring after initiation.

People who take several medicines for hypertension should not assume the additional tablet is irrelevant to their blood-pressure plan. Reporting headache, palpitations or a noticeable rise in readings can help the care team assess tolerability.

Urinary retention can occur, particularly in patients with bladder outlet obstruction or when used alongside certain other bladder medicines. New difficulty urinating, painful bladder distension or inability to pass urine needs prompt assessment. A patient with urgency and a weak stream may have more than one urinary problem, and treating urgency without checking emptying can be unsafe. Clinicians may evaluate residual urine or prostate-related symptoms where indicated.

Extended-Release Tablets

The catalog lists a 50 mg tablet strength, but the appropriate starting regimen can differ with patient factors and regional prescribing information. Mirabegron tablets are commonly extended-release and should be taken according to the product’s specific instructions.

Crushing, chewing or dividing an extended-release tablet can alter the intended release of medicine. Patients comparing generic and branded packages should verify that the release formulation is equivalent, not simply that both cartons show the same active ingredient.

Treatment may require several weeks before its full effect on urinary frequency and urgency can be assessed. Taking additional tablets after a difficult night is not an appropriate response. Follow-up may involve a bladder diary, blood-pressure measurements and discussion of residual symptoms. Some patients require a different treatment or further evaluation if urinary problems remain severe, but more medication cannot compensate for an incorrect diagnosis.

Urgency diaries that include fluid intake, nighttime voids and whether leakage occurs can help clinicians distinguish a useful response from a change in daily habits. Blood pressure readings and difficulty emptying the bladder deserve separate consideration.

Other Medicines and Monitoring

Mirabegron can influence the metabolism of certain medicines, including some drugs handled through CYP2D6 pathways. Patients taking medicines with narrow therapeutic ranges or complex cardiovascular regimens need medication reconciliation.

Kidney and liver function can also affect dosing recommendations. The safest prescription plan incorporates the person’s full medical history, not only the severity of urgency recorded in a symptom questionnaire.

Bladder control can improve unevenly. Nighttime frequency may respond differently from daytime urgency, and an improvement in leakage does not necessarily eliminate all bathroom visits.

The clinician may review whether fluid habits, constipation or sleep disorders are contributing. Regular assessment helps distinguish the benefit of treatment from normal changes in activity, travel or hydration that can temporarily alter urinary frequency.

Comparing Costs

Mexican Pharmacy King lists 4 selectable options for Myrbetriq (Mirabegron). The amounts shown below are the listed USD totals for several different strengths and quantities, not a prediction of what an unrelated pharmacy in Mexico will charge. Across the available combinations, the smallest listed total is $119.99 USD and the largest is $421.99 USD. These figures need to be checked again at ordering because availability, product specifications and final charges can change.

OptionQuantityListed total
50 mg30 pills$119.99 USD
50 mg90 pills$336.99 USD
50 mg120 pills$421.99 USD

The listed Myrbetriq presentations are extended-release tablets, so the tablet should not be crushed or divided to mimic a different dose. The available 50 mg options vary by count, which allows comparison of full-month and longer totals only when the prescription supports those quantities. A person beginning therapy may reasonably need a review before ordering far beyond the first follow-up, particularly where blood pressure or bladder-emptying symptoms are being monitored.

The lowest overall total and the lowest cost per unit are not necessarily the same offer. A quantity comparison is meaningful only when the strength, formulation and intended schedule match exactly, and a larger order should not exceed the prescription simply because the unit price appears more favorable. Currency conversion shown elsewhere on the site is a presentation of the listed amount, not an assurance of the exchange rate charged by a bank or payment service.

Ordering from Mexico

Pharmaceutical registration in Mexico is handled by COFEPRIS, which publishes a public register of authorized medicines. A name in a retail catalog does not by itself prove that a particular brand, batch or supplier is licensed, so the registration and the identifying details of the dispensed product should be checked independently. This also means that a medicine sold lawfully in Mexico is not automatically eligible for entry into another country. The applicable U.S. import rules and any prescription requirements must be confirmed before an international order is placed.

Safety Information

A qualified prescriber should reconcile allergies, chronic conditions and every current medication before treatment begins. If severe adverse symptoms develop, the appropriate response is medical assessment rather than trying another quantity or relying on an online product comparison. This page provides general medicine information, not an individualized dosing schedule or permission to substitute one registered product for another.

Bladder Treatment Questions

Does mirabegron treat a urinary tract infection? No. Urgency can have several causes, and an infection requires separate evaluation and treatment.

Can Myrbetriq be crushed? Extended-release tablets generally should be swallowed whole to preserve the intended release characteristics.

Why is blood pressure checked? Mirabegron may increase blood pressure and is not appropriate in some patients with severe uncontrolled hypertension.

What if it becomes hard to pass urine? New retention or markedly reduced urine flow warrants prompt clinical review.

Is the medicine the same as oxybutynin? No. Mirabegron activates beta-3 receptors, while oxybutynin is an antimuscarinic with a different adverse-effect profile.

Can buying 90 tablets replace follow-up? No. A longer supply is useful only if continued treatment is appropriate after evaluation of response and tolerability.

Further Reading

For product labeling, regulatory details and current patient guidance, consult MedlinePlus: Mirabegron and the COFEPRIS medicine registration lists. These resources should be read together with the instructions supplied by the licensed prescriber and the label for the dispensed product.